Cibc Asset Management Inc Alnylam Pharmaceuticals, Inc. Transaction History

Cibc Asset Management Inc

$28.3 Billion
Q3 2024

A detailed history of Cibc Asset Management Inc transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Cibc Asset Management Inc holds 4,483 shares of ALNY stock, worth $1.07 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,483

Previous 4,249 5.51%

Holding current value

$1.07 Million

Previous $1.03 Million 19.48%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 06, 2024	BUY	$233.81 - $287.01 $54,711 - $67,160	234 Added 5.51%	4,483 $1.23 Million
Q2 2024 Aug 01, 2024	BUY	$143.31 - $247.0 $32,531 - $56,069	227 Added 5.64%	4,249 $1.03 Million
Q1 2024 May 09, 2024	BUY	$146.51 - $198.2 $1,172 - $1,585	8 Added 0.2%	4,022 $601,000
Q4 2023 Feb 13, 2024	SELL	$151.41 - $196.57 $46,634 - $60,543	-308 Reduced 7.13%	4,014 $768,000
Q3 2023 Oct 30, 2023	BUY	$170.77 - $211.65 $21,858 - $27,091	128 Added 3.05%	4,322 $765,000
Q2 2023 Aug 14, 2023	BUY	$185.01 - $212.05 $555 - $636	3 Added 0.07%	4,194 $796,000
Q1 2023 May 12, 2023	BUY	$182.66 - $235.53 $15,343 - $19,784	84 Added 2.05%	4,191 $839,000
Q4 2022 Feb 13, 2023	SELL	$185.53 - $241.31 $222,450 - $289,330	-1,199 Reduced 22.6%	4,107 $976,000
Q3 2022 Nov 03, 2022	BUY	$138.54 - $232.0 $1,939 - $3,248	14 Added 0.26%	5,306 $1.06 Million
Q2 2022 Aug 09, 2022	SELL	$120.42 - $169.29 $11,439 - $16,082	-95 Reduced 1.76%	5,292 $772,000
Q1 2022 May 06, 2022	BUY	$127.18 - $173.91 $3,561 - $4,869	28 Added 0.52%	5,387 $880,000
Q4 2021 Feb 08, 2022	BUY	$159.56 - $209.29 $92,704 - $121,597	581 Added 12.16%	5,359 $909,000
Q3 2021 Nov 09, 2021	BUY	$169.75 - $207.73 $72,483 - $88,700	427 Added 9.81%	4,778 $902,000
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $1,414 - $1,945	11 Added 0.25%	4,351 $738,000
Q1 2021 May 14, 2021	BUY	$126.83 - $175.69 $20,419 - $28,286	161 Added 3.85%	4,340 $613,000
Q3 2020 Nov 05, 2020	BUY	$121.19 - $165.49 $12,482 - $17,045	103 Added 2.53%	4,179 $608,000
Q1 2020 Apr 30, 2020	SELL	$93.12 - $133.99 $65,090 - $93,659	-699 Reduced 14.64%	4,076 $444,000
Q4 2019 Feb 14, 2020	BUY	$74.51 - $124.23 $38,819 - $64,723	521 Added 12.25%	4,775 $550,000
Q3 2019 Oct 30, 2019	SELL	$70.9 - $87.82 $19,355 - $23,974	-273 Reduced 6.03%	4,254 $342,000
Q1 2019 May 06, 2019	BUY	$72.76 - $93.45 $40,745 - $52,332	560 Added 14.12%	4,527 $423,000
Q4 2018 Feb 12, 2019	SELL	$62.67 - $88.33 $940 - $1,324	-15 Reduced 0.38%	3,967 $289,000
Q3 2018 Nov 02, 2018	SELL	$87.52 - $122.67 $9,977 - $13,984	-114 Reduced 2.78%	3,982 $349,000
Q2 2018 Aug 09, 2018	BUY	$88.31 - $107.8 $41,064 - $50,127	465 Added 12.81%	4,096 $403,000
Q1 2018 Apr 30, 2018	BUY	$115.92 - $148.54 $62,712 - $80,360	541 Added 17.51%	3,631 $432,000
Q3 2017 Nov 06, 2017	BUY	$72.53 - $118.27 $224,117 - $365,454	3,090	3,090 $363,000

Others Institutions Holding ALNY

# of Institutions

644

Shares Held

109M

Call Options Held

1.28M

Put Options Held

1.21M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $29.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Asset Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cibc Asset Management Inc with notifications on news.

Account

Cibc Asset Management Inc Alnylam Pharmaceuticals, Inc. Transaction History